Physician profile
Sandi Lam
NPI 1699913343
$127,804.41
in general payments reported to CMS, 2019-2025
16 companies · $40K in 2025
The $40K reported for 2025 was more than what 94% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,031 · 2020: $3,706 · 2021: $24K · 2022: $65.06 · 2023: $2,708 · 2024: $50K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Travel and Lodging: $28K · Food and Beverage: $4,472 · Honoraria: $1,500 · Consulting Fee: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,698.00 |
| Travel and Lodging | $28,319.60 |
| Food and Beverage | $4,471.52 |
| Honoraria | $1,500.00 |
| Consulting Fee | $263.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $95,781.15 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Aesculap, INC. | $20,100.74 | 2020-2021 | |
| Aesculap Ag | $6,880.54 | 2019 | |
| Brainlab, INC. | $2,514.09 | 2021-2023 | Image Guided Surgical Device |
| Medtronic, INC. | $1,463.02 | 2024-2025 | Stealthstation S8 Platform, Stealth Autoguide System, Centerpiece Plate Fixation System |
| Insightec,INC | $259.04 | 2024-2025 | Exablate |
| Jazz Pharmaceuticals INC. | $196.40 | 2023 | Epidiolex |
| Monteris Medical Corporation | $187.90 | 2024 | Neuroblate |
| Neuropace, INC. | $181.73 | 2020-2021 | |
| Abbott Laboratories | $83.43 | 2023 | Infinity |
| Depuy Synthes Sales INC. | $71.63 | 2019 | |
| Biomarin Pharmaceutical INC. | $38.00 | 2020 | |
| Biocodex, INC. | $33.23 | 2025 | |
| Karl Storz Endoscopy-America | $13.51 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,812,566.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandi Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.